NCT02947152

HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of HKT288, Administered Intravenously in Adult Patients With Advanced Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A first-in-human study using HKT288 in solid tumors, including epithelial ovarian cancer and renal cell carcinoma

Conditions

• Epithelial Ovarian Cancer
• Renal Cell Carcinoma

Interventions

Type	Name	Description
DRUG	HKT288	Cadherin-6-targeting antibody-drug conjugate for intravenous administration

Timeline

• Start date: 2016-12-01
• Primary completion: 2017-09-14
• Completion: 2017-09-14
• First posted: 2016-10-27
• Last updated: 2020-12-08

Locations

6 sites across 6 countries: United States, Australia, Belgium, Japan, Spain, Switzerland

Regulatory

• FDA-regulated drug study